Rome-based venture capital firm Scientifica has launched a €200mn fund to support startups in quantum computing, artificial intelligence, and other frontier technologies. The fund, set to launch early next year, will provide early-stage companies with both financial backing and access to advanced lab spaces.

Scientifica's fund is based on a “Zero CapEx” model. Startups can use Scientifica's 4,000 m² of laboratories and a network of 70 certified labs in Italy without incurring upfront costs.

The aim is to reduce barriers to innovation by giving early-stage access to cutting-edge tools and facilities. The model reflects a growing trend of venture capital firms supporting both funding and infrastructure for startups, particularly in deep tech.

“Scientifica Fund is the tangible expression of a strategy that integrates research, venture capital, and industry to accelerate technological innovation and create sustainable value,” said managing partner Riccardo D'Alessandri, pictured above.

Scientifica already has three offices in Europe: two in Italy and another in London. It also recently expanded to Silicon Valley. Led by prominent entrepreneur and investor Jon Lunetta, the new hub aims to connect European startups with resources in the American tech ecosystem.

“With high-level international collaborations, we are ready to position Italy as a central player in the global innovation ecosystem,” said D'Alessandri.

One of Scientifica's key focus areas is in quantum computing startups. These companies are working on technologies that leverage quantum mechanics to process information in ways classical computers cannot. Scientifica's recently partnered with Quantum Italia, Italy's first VC focused entirely on quantum tech.   

Beyond quantum, Scientifica looks to back a range of technologies from AI and advanced materials to biotech and 3D printing. Among its current portfolio of 16 startups are Green Independence, a startup developing an artificial “solar leaf” with a built-in wastewater purification system, and Recornea, which is working on an implant to treat a severe eye condition called keratoconus.